Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

1cP-AL-LAD

1cP-AL-LAD molecule structure1cP-AL-LAD molecule structure
1-Cyclopropionyl-6-allyl-6-nor-lysergic acid diethylamide
Psychoactive Class
PsychedelicHallucinogen
Chemical Class
Lysergamide

1cP-AL-LAD is a novel semisynthetic psychedelic of the lysergamide class.citation needed It is structurally related to AL-LAD1 and is suspected to act as a prodrug for that compound, though this has not been confirmed by formal research. First identified in France in June 2021, it emerged alongside several other novel lysergamides as a designer drug.citation needed Very little anecdotal or scientific data is currently available regarding its effects.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~20 µg
Light50-100 µg
Moderate100-225 µg
Strong225-350 µg
Heavy350+ µg

Duration

Onset20-60 minutes
Come Up30-60 minutes
Peak2.5-5 hours
Offset2-3 hours
After Effects2-18 hours
Total7-10 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

Increased bodily control

Cognitive

In comparison to other psychedelics such as Psilocin, LSA and Ayahuasca, 1cP-AL-LAD is significantly more stimulating and fast paced in terms of the specific style of thought stream which it produces and contains a large number of potential effects.

Enhancement of current mind stateAcceleration of thoughtFeelings of fascination, importance and aweTime distortionIntrospectionDéjà vuMultiple thought streamsRemoval of cultural filterConceptual thinkingEgo suppression, loss and deathThought loopsFeelings of interdependent oppositesDelusionsStates of unity and interconnectedness

Visual

Distortions

Enhancements

Geometry

The visual geometry that is present throughout this trip can be described as more similar in appearance to that of 2C-B or 2C-I than Psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful in scheme, organic in feel, multicoloured in scheme, flat in shading, soft in its edges, large in size, slow in speed, smooth in motion, round in its corners, unimmersive in depth and consistent in intensity. At higher dosages, it consistently results in states of Level 8A visual geometry over Level 8B.

Hallucinatory States

1cP-AL-LAD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.

Transformations

Auditory

The auditory effects of 1cP-AL-LAD are common in their occurrence and exhibit a full range of effects.

EnhancementsDistortionsHallucinations
Adapted from the AL-LAD subjective effects documentation. 1cP-AL-LAD is a suspected prodrug of AL-LAD and is reported to produce an effectively identical experience. Forked from Subjective Effect Documentation byJosie Kins July 2014.

See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
No reaction
No reaction
Mecke(ME)
No reaction
No reaction
Ehrlich(EH)
No reaction
No reaction
Hofmann(HM)
No reaction
No reaction
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

1cP-AL-LAD likely acts as a partial agonist at the serotonin 5-HT2A receptor, which is believed to underlie its psychedelic effects. The substance is suspected to function as a prodrug for AL-LAD based on its 1-cyclopropionyl substitution, analogous to 1cP-LSD's proposed conversion to LSD. However, there is currently insufficient data to confirm this prodrug relationship definitively.citation needed

Pharmacokinetics

1cP-AL-LAD is suspected to undergo metabolic conversion to AL-LAD via removal of its 1-cyclopropionyl group, though this prodrug mechanism has not been confirmed with sufficient evidence.citation needed

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

Lithium

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Tramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

AmphetaminesCannabisCocaineDiphenhydramineMephedronePregabalin
Powered by TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
1cP-AL-LAD can produce tolerance very rapidly after it is taken.
Baseline Reset
Around 14 days of abstinence are required to return to baseline tolerance, assuming no further consumption during this period.
Half Tolerance
Approximately 5-7 days for tolerance to reduce to half of its peak level.
Cross Tolerance

Serotonergic psychedelics

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

Presumed non-addictive based on its similarity to LSD.citation needed Anecdotal evidence suggests the desire to use it may actually decrease with repeated use.

Physical

Extremely Low

No evidence of physical dependence. As with LSD, physical dependence is not expected to develop.citation needed

Psychosis Risk

May act as a potential trigger for psychosis in those with underlying psychiatric conditions.citation needed Those with a personal or family history of mental illness are advised not to use this substance outside of supervised medical settings. Adverse psychological reactions including delusions and panic attacks become more likely at higher doses.

Seizure Risk

Seizures are rare but have been reported.citation needed Risk is thought to be primarily in those genetically predisposed to seizures, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment.

History & Culture

1cP-AL-LAD is a novel lysergamide that emerged as part of the designer drug market in the early 2020s.2 The compound is believed to have been first synthesized around 2020 or 2021, reportedly by chemists who were also developing other novel lysergamides…

Legality

By Country

Illegal2
Austria flagAustriaIllegal (analog/blanket ban)
Germany flagGermanyIllegal (analog/blanket ban)
Controlled / restricted1
Switzerland flagSwitzerlandControlled (Verzeichnis E)
Not scheduled1
United States flagUnited StatesUnscheduled

References

Source Pages

  1. 300 µg sublingual trip report (Bluelight)
  2. AL-LAD dose & 6-8 h duration
  3. Isomer Design (TiHKAL/PiHKAL)
  4. PsychonautWiki
  5. Wikipedia

Citations

  1. Pierce V. Kavanagh, Folker Westphal, Benedikt Pulver, Hannes M. Schwelm, Alexander Stratford, Volker Auwärter, Stephen J. Chapman, Adam L. Halberstadt, & Simon D. Brandt. (March 2023). Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities. Drug Test Anal, 15(3), 277–291. https://doi.org/10.1002/dta.33971
  2. 1cP-AL-LAD. АИПСИН (n.d.). https://aipsin.com/newsubstance/595/1
  3. Neue-Psychoaktive-Substanzen-Verordnung (NPSV), consolidated Austrian text, version 27 August 2026. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/geltendefassung/bundesnormen/20007642/npsv%2C%20fassung%20vom%2027.08.2026.pdf1
  4. Neue-Psychoaktive-Substanzen-Verordnung, Anlage II (BGBl. II Nr. 106/2024). ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf1
  5. Neue-Psychoaktive-Substanzen-Gesetz § 3 (RIS), current Austrian text. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/eli/bgbl/i/2011/146/P3/NOR401344461
  6. Neue-Psychoaktive-Substanzen-Gesetz § 4 (RIS), current Austrian text. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/eli/bgbl/i/2011/146/P4/NOR401344471
  7. Neue-Psychoaktive-Substanzen-Gesetz § 5 (RIS), current Austrian text. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/eli/bgbl/i/2011/146/P5/NOR401344481
  8. Neue-Psychoaktive-Substanzen-Gesetz (NPSG), consolidated Austrian text, version 27 August 2026. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/geltendefassung/bundesnormen/20007605/npsg%2C%20fassung%20vom%2027.08.2026.pdf1
  9. Bundesrat Drucksache 403/21: Zweite Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes. dserver.bundestag.de (n.d.). https://dserver.bundestag.de/brd/2021/0403-21.pdf1
  10. Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1

Further Reading

  1. 600 µg 1cP-AL-LAD timeline (Reddit)
  2. Analytical profile of 1cP-AL-LAD
  3. Detection of LSD analogs 1cP-AL-LAD, 1cP-MIPLA
  4. First-time 150 ug report
  5. Identification of 1cP-AL-LAD in Japanese blotters
  6. In-vitro conversion of 1P-AL-LAD to AL-LAD (proxy)
  7. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of LSD
  8. Return of the Lysergamides VI (metabolism parallels)
  9. TrippyWiki: user-collated harm-reduction info

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Lyrea avatar
    Step 2 · First-pass review

    A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest

Times are UTCNewest first

24 July 2026

  1. Lyrea · Updated the article · also 1cP-LSD, 1cP-MiPLA, 1P-ETH-LAD

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-LSD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-LSD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-LSD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-LSD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-LSD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-LSD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-LSD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 1cP-AL-LAD article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.